cas 843644-23-5|| where to buy 6,8-difluoro-3,4-dihydronaphthalen-2(1H)-one

Nombre del producto:6,8-difluoro-3,4-dihydronaphthalen-2(1H)-one

IUPAC Name:6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-one

Unidad de embalaje	Stock disponible	Precio($)
CM124434-1g	in stock	ǸŮ
CM124434-5g	in stock	ǟŽŌ
CM124434-10g	in stock	ĳĳŌ
CM124434-25g	in stock	ǸŮǟ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 843644-23-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :843644-23-5; Fórmula molecular:C10H8F2O; Punto de fusión:-; Código de sonrisas:O=C1CC2=C(C=C(F)C=C2F)CC1; Densidad:

: Número de catálogo:CM124434; Peso molecular:182.17; Punto de ebullición:; Nº Mdl:MFCD05663016; Almacenamiento:

: Naphthalenes; Naphthalene is a hydrocarbon produced by the distillation of coal tar and is an aromatic white crystalline substance. Naphthalene is the most abundant component in coal tar. It is used as an insect repellant and insect fumigant. The compound is used in the manufacture of celluloid, dyes, hydrogenated naphthalenes, oil fumes, smokeless powders and synthetic resins.

: Ogsiveo; The FDA has approved Ogsiveo (Nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. The FDA approval of Ogsiveo is based on the results from the Phase 3 DeFi trial. The results showed that Ogsiveo met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). Ogsiveo is an oral, selective, small molecule gamma secretase inhibitorγ. Gamma secretase cleaves multiple transmembrane proteins, including Notch, that are believed to play a role in activating pathways that contribute to growth of desmoid and ovarian granulosa cell tumors.